Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128981 | 0.80 | MEN1 (0.53) | DHFRHSD11B1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3184997 | 0.76 | DHFR (0.53) | DHFRHSD11B1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5987851 | 0.70 | DHFR (0.48) | DHFRHSD11B1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23975531 | 0.70 | DHFR (0.48) | DHFRHSD11B1OPRK1OPRM1KCNH2 | |
| SCHEMBL1025178 | 0.70 | DHFR (0.54) | DHFRHSD11B1TNK2KDM4C | |
| SCHEMBL22702800 | 0.69 | MGLL (0.48) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL21029363 | 0.69 | MGLL (0.48) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20270278 | 0.69 | MGLL (0.48) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL19833673 | 0.69 | MGLL (0.48) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20128978 | 0.68 | MEN1 (0.50) | DHFRHSD11B1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | DHFR 2815/4885HSD11B1 4133/4885SLC6A4 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.